ROS1 and non-small cell lung carcinoma: In 2019, entrectinib (Rozlytrek) joined the list of tumor-agnostic therapies approved for NTRK fusion-positive tumors and ROS1-positive non-small cell lung cancer (NSCLC), including those with central nervous system metastases [4].